RT Journal Article
T1 MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
A1 San José-Enériz, Edurne
A1 Román-Gómez, José
A1 Jiménez-Velasco, Antonio
A1 Garate, Leire
A1 Martin, Vanesa
A1 Cordeu, Lucia
A1 Vilas-Zornoza, Amaia
A1 Rodríguez-Otero, Paula
A1 Calasanz, María José
A1 Prósper, Felipe
A1 Agirre, Xabier
K1 Antineoplásicos
K1 Análisis de cluster
K1 Resistencia a antineoplásicos
K1 Leucemia mielogenosa crónica BCR-ABL positiva
K1 MicroARN
K1 Pirimidinas
K1 Reacción en cadena de la polimerasa de transcriptasa inversa
K1 Perfiles de expresión génica
AB The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML. In this study, we have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML.
PB BioMed Central
YR 2009
FD 2009-09-01
LK http://hdl.handle.net/10668/1209
UL http://hdl.handle.net/10668/1209
LA en
NO San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol. Cancer. 2009; 8:69
NO Additional file 1Expression of 250 miRNAs in resistant and responder CML patients. The data provided represent the expression of microRNA.
DS RISalud
RD Apr 9, 2025